For younger, active patients the Furlong Evolution® is supported by superior clinical results[1]

FURLONG EVOLUTION

jri Orthopaedics

An AK MEDICAL Company

Furlong Evolution®, your first choice

The 2022 National Joint Registry 19th Annual Report indicated that a total of 3229 patients received Ceramic on Ceramic (CoC) bearing uncemented total hip replacements. The mean age of this patient group was 58.6, younger than any other bearing surface used in primary surgery for this period.[1]

- Successfully implanted since 2010, the Furlong Evolution® femoral stem provides the solution for surgeons demanding a bone conserving stem.[2] The implant and instrument platforms are designed for conventional and modern tissue sparing approaches.
- Primary stability and longer-term biological fixation is assured through JRI Orthopaedics' unique Supravit® Zoned H-A.C coating, which has been developed and advanced over 35+ years.[3-4]
- Restoration of joint biomechanics and soft tissue tension is managed through standard and high-offset stems.[5-7]
- Precise instrumentation promotes reproducible and predictable outcomes for surgeon and patient. Efficiency in theatre, value in practice, and accuracy in surgery is enhanced with Naviswiss Hip Navigation.[8]

Furlong Evolution®

Key Findings

Across all patient age groups, in particular those aged <55 and 55-64, the Furlong Evolution® CoC construct demonstrated a substantially reduced cumulative revision rate at 10 years (Table 1)[9], when compared to all other CoC bearing uncemented stems in the National Joint Registry (NJR).[1]

Table 1.
Kaplan-Meier estimates of cumulative revision (95% confidence limits) at 10 years of different patient age groups for the Furlong Evolution® Femoral Stem compared to all other CoC bearing uncemented stems in the NJR.

Blue italics signify that fewer than 40 cases remained at risk at 10 years.

Patient Age	<55	55-64	65-74	>75	Overall
Furlong Evolution®[9]*	1.98% (1.24-3.18%)	1.61% (1.03-2.52%)	2.00% (1.32-3.04%)	*2.88% (1.49-5.56%)*	1.97% (1.53-2.53%)
All other CoC bearing uncemented femoral stems[1] (M: Male; F: Female)	M = 4.27% (3.96-4.60%) F = 4.03% (3.74-4.35%)	M = 3.51% (3.25-3.79%) F = 2.92% (2.70-3.15%)	M = 2.94% (2.66-3.25%) F = 2.45% (2.21-2.70%)	M = 3.53% (2.84-4.37%) F = 2.97% (2.43-3.62%)	3.36% (3.25-3.47%)
Furlong Evolution®[9]* (Femoral Revised)	0.85% (0.45-1.59%)	1.18% (0.70-1.99%)	1.28% (0.79-2.05%)	*1.49% (0.64-3.47%)*	1.13% (0.85-1.52%)
Furlong Evolution®[9]* Mean Age (Years)	43.4	59.6	69.3	78.9	59.2

*Analysis of NJR Supplier Feedback Data for Furlong Evolution® primary procedures between 29-Jan-2011 to 25-Nov-2022.

Disclaimer:

The data used for this analysis was obtained from the National Joint Registry ("NJR"), part of the Healthcare Quality Improvement Partnership ("HQIP"). HQIP, the NJR and/or its contractor, NEC Software Solutions (UK) Limited ("NEC") take no responsibility (except as prohibited by law) for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation including any duty of care to third party readers of the data analysis.

References:

[1] National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man. 2022. National Joint Registry 19th Annual Report 2022. [Online]. 19th ed. [Accessed 7 February 2023]. Available from: https://reports.njrcentre.org.uk/

[2] Gómez-Vallejo, J., Roces-García, J., Moreta, J., Donaire-Hoyas, D., Gayoso, Ó., Marqués-López, F. and Albareda, J. 2021. Biomechanical Behavior of an Hydroxyapatite-Coated Traditional Hip Stem and a Short One of Similar Design: Comparative Study Using Finite Element Analysis. Arthroplasty Today. 7, pp.167–176.

[3] Sandiford, N., Doctor, C., Rajaratnam, S.S., Ahmed, S., East, D.J., Miles, K., Butler-Manuel, A. and Shepperd, J.A. (2013). Primary total hip replacement with a Furlong fully hydroxyapatite-coated titanium alloy femoral component: Results at a minimum follow-up of 20 years. The Bone & Joint Journal. 95-B(4), pp.467–471.

[4] Rajaratnam, S.S., Jack, C., Tavakkolizadeh, A., George, M.D., Fletcher, R.J., Hankins, M. and Shepperd, J.A. 2008. Long-term results of a hydroxyapatite-coated femoral component in total hip replacement: a 15- to 21-year follow-up study. The Journal of Bone and Joint Surgery. British volume. 90(1), pp.27–30.

[5] Belfrage, O., Weber, E., Sundberg, M. and Flivik, G. 2021. Preserved periprosthetic bone stock at 5 years post-operatively with uncemented short hip stem in both collared and collarless version. Archives of Orthopaedic and Trauma Surgery. 142(11), pp.3489–3496.

[6] Wiik, A.V., Aqil, A., Al-Obaidi, B., Brevadt, M. and Cobb, J.P. 2021. The impact of reducing the femoral stem length in total hip arthroplasty during gait. Archives of Orthopaedic and Trauma Surgery. 141(11), pp.1993-2000.

[7] Weber, E., Flivik, C., Sundberg, M. and Flivik, G. 2019. Migration pattern of a short uncemented stem with or without collar: a randomised RSA-study with 2 years follow-up. Hip international: the journal of clinical and experimental research on hip pathology and therapy. 31(4), pp.500–506.

[8] Hasegawa, M., Naito, Y., Tone, S. and Sudo, A. 2022. Accuracy of a novel accelerometer-based navigation (Naviswiss) for total hip arthroplasty in the supine position. BMC musculoskeletal disorders. 23(1), pp.1-7.

[9] National Joint Registry Supplier Feedback System. 2023. H_CRC_Primary_Outcomes_Hip - Stems Cementless_Furlong Evolution Cementless_2745_20221212. [Online]. [Accessed 9 January 2023]. Available from: https://platform.njrcentre.org.uk/

Manufactured & Distributed by

jri Orthopaedics
An AK MEDICAL Company

JRI Orthopaedics Ltd.
18 Churchill Way, 35A Business Park, Chapeltown, Sheffield, UK S35 2PY
T: 0114 345 0000 E: jri@jri-ltd.co.uk W: www.jri-ltd.com